@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix go: . @prefix scomp: . @prefix ProteinComplex: . @prefix hasAgent: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { scomp:p85%2Fp110%20PI3Kinase%20Complex a ProteinComplex: . sub:_1 hasAgent: scomp:p85%2Fp110%20PI3Kinase%20Complex; a go:0016301 . sub:_2 hasAgent: sub:_3; a go:0005525 . sub:_3 geneProductOf: hgnc:9801; a Protein: . sub:_4 occursIn: obo:UBERON_0004852, species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "kin(complex(SCOMP:\"p85/p110 PI3Kinase Complex\")) -> gtp(p(HGNC:RAC1))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_6; pav:version "20131211" . sub:_5 prov:value "As expected, CDC42 and Rac1 activation mediated by EGLT can be completely inhibited by PI3K inhibitors, wortmannin and LY294002, and the p85 dominant negative mutant but not by either the phospholipase C inhibitor, or an intracellular Ca(2+) chilator BAPTA/AM."; prov:wasQuotedFrom pubmed:11726672 . sub:_6 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:11726672; prov:wasDerivedFrom beldoc:, sub:_5 . } sub:pubinfo { this: dct:created "2014-07-03T14:31:45.056+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }